RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non‐Metastatic Ovarian Cancer in Mice

ABSTRACT Tumor‐ and bone‐derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone‐targeting agents, such...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of bone and mineral research Jg. 37; H. 3; S. 381 - 396
Hauptverfasser:	Pin, Fabrizio, Jones, Alexander J, Huot, Joshua R, Narasimhan, Ashok, Zimmers, Teresa A, Bonewald, Lynda F, Bonetto, Andrea
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Hoboken, USA John Wiley & Sons, Inc 01.03.2022 Oxford University Press
Schlagworte:	Animals Antineoplastic drugs ANTIRESORPTIVE TREATMENTS Antitumor agents Atrophy Bisphosphonates Body composition BONE Bone Diseases, Metabolic - pathology Bone loss Bone mass Bone resorption Bone tumors Bone turnover CACHEXIA Cachexia - complications Cachexia - drug therapy CANCER Collagen Drug development Female Humans Ligands Metastases Metastasis Mice MUSCLE Muscle, Skeletal - pathology Muscular Atrophy - pathology Musculoskeletal system Myotubes Ovarian cancer Ovarian Neoplasms - complications Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology RANKL Skeletal muscle Therapeutic targets TRANCE protein MUSCLE CACHEXIA RANKL BONE ANTIRESORPTIVE TREATMENTS CANCER
ISSN:	0884-0431, 1523-4681, 1523-4681
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!